If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Dispatch of General Meeting Documents

13 Feb 2024 10:00

RNS Number : 9635C
MGC Pharmaceuticals Limited
13 February 2024

MGC Pharmaceuticals Ltd.

Dispatch of General Meeting Documents

13 February 2024

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to advise that it has dispatched the following documentation related to the General Meeting of shareholders to be held at 3:00pm (AWST) on Monday, 18 March 2024 at Suite 1, 295 Rokeby Road, Subiaco Western Australia 6008, to eligible shareholders.

A copy of which can be found at the following URL: https://www.investi.com.au/api/announcements/mxc/26603a17-de0.pdf

-ENDS-

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland

Company Secretary

+61 8 6382 3390

info@mgcpharma.co.uk

UK IR/PR Advisers

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen

+44 203 934 6630

mgcpharma@investor-focus.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock

+44 203 179 5300

aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCGCGDDBGBDGSX
Date   Source Headline
18th Feb 20214:40 pmRNSSecond Price Monitoring Extn
18th Feb 20214:35 pmRNSPrice Monitoring Extension
18th Feb 202111:05 amRNSSecond Price Monitoring Extn
18th Feb 202111:00 amRNSPrice Monitoring Extension
18th Feb 20219:05 amRNSSecond Price Monitoring Extn
18th Feb 20219:00 amRNSPrice Monitoring Extension
18th Feb 20217:00 amRNSWorldwide distribution agreement of ArtemiC Rescue
17th Feb 20214:41 pmRNSSecond Price Monitoring Extn
17th Feb 20214:36 pmRNSPrice Monitoring Extension
16th Feb 20217:00 amRNSLSE Dual Listing & Depositary Interest Information
15th Feb 20217:00 amRNSExpansion of Glioblastoma research program
12th Feb 20214:41 pmRNSSecond Price Monitoring Extn
12th Feb 20214:35 pmRNSPrice Monitoring Extension
12th Feb 20219:05 amRNSSecond Price Monitoring Extn
12th Feb 20219:00 amRNSPrice Monitoring Extension
12th Feb 20217:00 amRNSMGC Pharma Investor Presentation Today - 10am
11th Feb 20212:06 pmRNSSecond Price Monitoring Extn
11th Feb 20212:00 pmRNSPrice Monitoring Extension
11th Feb 20219:05 amRNSSecond Price Monitoring Extn
11th Feb 20219:00 amRNSPrice Monitoring Extension
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:36 pmRNSPrice Monitoring Extension
9th Feb 20218:02 amRNSMGC Pharma Investor Presentation -12/02/2021
9th Feb 20217:00 amRNSAdmission to the LSE & First Day of Trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.